Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMTOX25 in Relapsed/Refractory Cutaneous T-Cell Lymphoma
NCT00667017Phase 2Terminated
- Sponsor
- UT Southwestern Medical Center
- Start
- Nov 2008
- Primary completion
- Feb 2010
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of RFT5-SMPT-dgA in cutaneous T-cell lymphoma (CTCL), sponsored by UT Southwestern Medical Center. Started Nov 2008; status: terminated.
02
Drugs
RFT5-SMPT-dgA
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT00667017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00667017.